Resumen de negocios
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Immunotherapies
100,0
%
| 6 | 100,0 % | 7 | 100,0 % | +9,58 % |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 6 | 100,0 % | 7 | 100,0 % | +9,58 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Jeff Wolf
CEO | Chief Executive Officer | 60 | 10/06/08 |
Director of Finance/CFO | 56 | 25/09/19 | |
David Waldman
IRC | Investor Relations Contact | - | - |
George Peoples
PRN | Corporate Officer/Principal | - | - |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
John Prendergast
BRD | Director/Board Member | 70 | 26/04/16 |
Jeff Wolf
CEO | Chief Executive Officer | 60 | 10/06/08 |
Edward Smith
BRD | Director/Board Member | 48 | 01/01/09 |
John Monahan
BRD | Director/Board Member | 77 | 01/11/09 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 96 664 869 | 92 825 739 ( 96,03 %) | 0 | 96,03 % |
Información de la empresa
Scorpius Holdings, Inc.
627 Davis Drive Suite 300
27560, Morrisville
+919 240 7133
http://ww.ir.scorpiusbiologics.comSector
Varia. 1 de ene. | Capi. | |
---|---|---|
+6,87 % | 72,01 mil M | |
+30,80 % | 10,39 mil M | |
+40,84 % | 5255,13 M | |
-18,53 % | 4635,09 M | |
+12,65 % | 3702,19 M | |
+27,58 % | 2296,11 M | |
-39,96 % | 1798,64 M | |
-45,87 % | 1702,05 M | |
-0,50 % | 1644,13 M |